AI-Driven Early Detection of Skin Cancer
ConditionSkin Cancer Melanoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorNuvana Healthcare LTD
About this trial
This study evaluates the feasibility and accuracy of an AI-powered mobile platform (NuvanaDx) for early detection of skin cancer, including melanoma, using smartphone-based imaging. The platform is designed to improve access to early diagnosis, reduce waiting times, and support triage into appropriate care pathways.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
Study Population Description: Individuals undergoing dermatology evaluation in UK clinics, supplemented by retrospective anonymized image datasets.
Trial design
Design model
Ecologic or community
Time perspective
Prospective
Treatments tested in this trial
Smartphone-based AI skin lesion analysis (NuvanaDx platform).
Diagnostic testSmartphone-based AI skin lesion analysis (NuvanaDx platform).
Treatment groups
100 Participants
are divided into 1 treatment groupGroup A: Participants with suspicious skin lesions undergoing AI-based image analysis and dermatologist confi1 intervention
Trial outcomes
Primary outcomes
1
Diagnostic Accuracy of AI tool compared with dermatologist-confirmed diagnosis
Diagnostic Accuracy of AI tool compared with dermatologist-confirmed diagnosis Time Frame: Up to 12 months Measure: Sensitivity, specificity, and predictive values
Time frame
Time Frame: Up to 12 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Nuvana Healthcare LTD
Lead sponsor
National Institute for Health Research, United Kingdom
Collaborator
Source ClinicalTrials.gov